Akero Therapeutics, Inc. (AKRO) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2025-12-09

Akero Therapeutics, Inc. (AKRO) — no SEC Form 4 insider filings recorded in the last 90 days. InsiderAlpha tracks every AKRO SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Akero Therapeutics, Inc. (AKRO)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001744659

Recent AKRO Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-12-09	Rolph Timothy	Chief Scientific Officer	D — Derivative transaction	43.8K	—	—	SEC
2025-12-09	Rolph Timothy	Chief Scientific Officer	D — Derivative transaction	238.3K	—	—	SEC
2025-12-09	Young Jonathan	Chief Operating Officer	D — Derivative transaction	152.6K	—	—	SEC
2025-12-09	Young Jonathan	Chief Operating Officer	D — Derivative transaction	47.6K	—	—	SEC
2025-12-09	White William Richard	Chief Financial Officer	D — Derivative transaction	10.2K	—	—	SEC
2025-12-09	White William Richard	Chief Financial Officer	D — Derivative transaction	47.6K	—	—	SEC
2025-12-09	Yale Catriona	Chief Development Officer	D — Derivative transaction	47.6K	—	—	SEC
2025-12-09	Lamy Patrick	See Remarks	D — Derivative transaction	3.1K	—	—	SEC
2025-12-09	Young Jonathan	Chief Operating Officer	D — Derivative transaction	20.0K	—	—	SEC
2025-12-09	Young Jonathan	Chief Operating Officer	D — Derivative transaction	20.0K	—	—	SEC
2025-12-09	Yale Catriona	Chief Development Officer	D — Derivative transaction	27.2K	—	—	SEC
2025-12-09	Young Jonathan	Chief Operating Officer	D — Derivative transaction	20.0K	—	—	SEC
2025-12-09	Lamy Patrick	See Remarks	D — Derivative transaction	26.8K	—	—	SEC
2025-12-09	Henderson Jane	Insider	D — Derivative transaction	9.4K	—	—	SEC
2025-12-09	Iwicki Mark T	Insider	D — Derivative transaction	9.4K	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Akero Therapeutics, Inc. (AKRO). Updated in real time as new filings are submitted to the SEC.

Recent Insider Filings

2025-12-09 — Heyman Tomas J. (Insider)
2025-12-09 — Xu Yuan (Insider)
2025-12-09 — Cheng Andrew (President and CEO)
2025-12-09 — Harrison Seth Loring (Insider)
2025-12-09 — Graham G. Walmsley (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in AKRO insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

AKRO Insider Trading — FAQ

What is the latest insider trade for AKRO?: Akero Therapeutics, Inc. (AKRO) had 0 insider filings in the last 90 days, with the most recent on 2025-12-09. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying AKRO stock?: 0 insider purchases of AKRO were filed in the last 90 days.
How many insiders are selling AKRO stock?: 0 insider sales of AKRO were filed in the last 90 days.
Where can I see AKRO SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every AKRO SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live AKRO dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.